Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma.
Vanita Noronha(Homi Bhabha National Institute), Kumar Prabhash(Homi Bhabha National Institute), Vijayalakshmi Mathrudev, Vedang Murthy(Homi Bhabha National Institute), Suman Kumar(Army Hospital Research and Referral), Jaiprakash Agarwal(Tata Memorial Hospital), Munita Bal(Post Graduate Institute of Medical Education and Research), Sunil Chopade(Tata Memorial Hospital), Asawari Patil(Tata Memorial Hospital), Abhishek Mahajan(Tata Memorial Hospital), Neha Mittal(Homi Bhabha National Institute), Nandini Sharrel Menon(Tata Memorial Hospital), Ashwini Budrukkar(Tata Memorial Hospital), Ajaykumar Singh(Tata Memorial Hospital), Vijay Patil(Homi Bhabha National Institute), Tejpal Gupta(Tata Memorial Hospital), Kavita Nawale, Sarbani Ghosh Laskar(Tata Memorial Hospital)
Cited by 3
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
|European Urology|2020|396
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
|European Journal of Nuclear Medicine and Molecular Imaging|2011|377
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
|Journal of Clinical Oncology|2017|340